Smoking cessation treatments and alcohol drinking

戒烟治疗和饮酒

• 批准号: 7033211
• 负责人: SHERRY ANN MCKEE
• 金额: $ 29.46万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-05 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7033211
• 关键词: adult human (21+); alcoholic beverage consumption; alcoholism /alcohol abuse; alcoholism /alcohol abuse chemotherapy; antidepressants; bupropion; clinical research; combination chemotherapy; comorbidity; craving; drug screening /evaluation; drug withdrawal; emotions; human subject; human therapy evaluation; inhalation drug administration; nicotine replacement; patient oriented research; psychopharmacology; smoking; smoking cessation; substance abuse related behavior; tobacco abuse; transdermal drug delivery

DESCRIPTION (provided by applicant): Given the substantial health risks associated with concurrent alcohol and tobacco use, there has been a growing effort to address smoking cessation in those experiencing alcohol problems. Non-dependent hazardous drinkers have high rates of concurrent smoking and represent 80% of those who experience alcohol-related problems. Little is known about how best to promote smoking cessation in this population of drinkers who are at increased risk for poor smoking cessation outcomes. Pharmacotherapies for smoking cessation may promote improved quit rates in hazardous drinking smokers by reducing alcohol reactivity and consumption, thereby attenuating the ability of alcohol to prompt smoking relapse. Support for this project comes from a study by our group where we examined whether transdermal nicotine replacement ( 0 mg, 21 mg) altered reactivity to a fixed low dose of alcohol and subsequent ad-libitum consumption in moderate to heavy drinkers. Results demonstrated that 21 mg nicotine patch, compared to 6 hours of nicotine deprivation (placebo patch), decreased reactivity to the priming drink and reduced subsequent ad-libitum consumption. Current clinical practice guidelines indicate that combined nicotine replacement therapy (e.g., patch +nasal spray) and bupropion are two of the most efficacious pharmacotherapies available for smoking cessation. However, there is no research to date that has examined the effect of these two smoking cessation treatments on alcohol reactivity and self-administration behavior. Using similar procedures to our completed R03 project, the primary aim of STUDY 1 will be to examine whether 21 mg patch + nicotine spray, compared to 21 mg patch + placebo spray, alters reactivity to alcohol (.03g/dl priming drink) and subsequent ad-libitum drinking in individuals who are non-depndent hazardous drinking smokers. Specifically we will examine the effect of combined nicotine replacement on 1) ad-libitum alcohol consumption and alcohol craving, 2) tobacco craving and nicotine withdrawal, and 3) subjective intoxication and mood. STUDY 2 will be of similar design and aims examining bupropion (SOOmg vs. Omg). This proposal will have important treatment implications for improving rates of smoking cessation in hazardous drinkers and will contribute to the understanding of alcohol-nicotine interactions.

描述（由申请人提供）：考虑到同时饮酒和吸烟会带来巨大的健康风险，人们越来越努力地解决那些有酗酒问题的人的戒烟问题。非依赖性危险饮酒者同时吸烟的比例很高，占那些经历酒精相关问题的人的 80%。对于如何最好地促进戒烟效果不佳的饮酒者群体的戒烟知之甚少。戒烟药物疗法可以通过减少酒精反应性和消耗量，从而减弱酒精促使吸烟复吸的能力，从而提高危险饮酒吸烟者的戒烟率。对这个项目的支持来自我们小组的一项研究，我们研究了透皮尼古丁替代品（0 毫克、21 毫克）是否改变了中度至重度饮酒者对固定低剂量酒精的反应以及随后的随意消费。结果表明，与 6 小时剥夺尼古丁（安慰剂贴片）相比，21 毫克尼古丁贴片降低了对启动饮料的反应性，并减少了随后的随意消费。 目前的临床实践指南表明，联合尼古丁替代疗法（例如贴片+鼻喷雾剂）和安非他酮是两种最有效的戒烟药物疗法。然而，迄今为止还没有研究检验这两种戒烟治疗对酒精反应和自我给药行为的影响。使用与我们已完成的 R03 项目类似的程序，研究 1 的主要目的是检查 21 毫克贴片 + 尼古丁喷雾与 21 毫克贴片 + 安慰剂喷雾相比是否会改变对酒精（0.03g/dl 启动饮料）和随后的反应性非依赖性危险饮酒吸烟者的随意饮酒。具体来说，我们将检查联合尼古丁替代对 1) 随意饮酒和酒精渴望，2) 烟草渴望和尼古丁戒断，以及 3) 主观中毒和情绪的影响。研究 2 将采用类似的设计，旨在检查安非他酮（SOOmg 与 Omg）。该提案对于提高危险饮酒者的戒烟率具有重要的治疗意义，并将有助于理解酒精-尼古丁相互作用。